SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

ENDRA Life Sciences 8-K Filing

ENDRA Life Sciences files 8-K with material definitive agreement and unregistered equity sales. Filing includes financial statements and exhibits.

NDRA
SquawkNews Desk

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories

BNY Mellon Reports Third-Quarter 2026 Revenue of $5.68 Billion Revenue rose 11.7% year over year to $5.68 billion. Net income attributable to common shareholders increased 20.1% to $1.61 billion, and diluted EPS rose 24.5% to $2.34. M impact | EQUITY | Oct 30, 2026, 11:11 AM UTC Exxon Mobil Q3 Adjusted Earnings Beat Estimates, Revenue Rises Exxon Mobil reported Q3 adjusted earnings Friday; revenue rose. M impact | EQUITY | Oct 30, 2026, 11:08 AM UTC HSBC Upgrades GE Vernova to Buy, Raises Price Target to $1,100 HSBC raised its price target from $1,040 to $1,100, citing gas demand and a less risky outlook for the wind business. H impact | EQUITY | Oct 30, 2026, 11:06 AM UTC AstraZeneca Reports Third-Quarter Revenue of $16.21B M impact | EQUITY | Oct 30, 2026, 11:05 AM UTC BofA Securities Downgrades NMI Holdings to Neutral, Cuts Target to $44 BofA Securities lowered its price target from $51 to $44. The revised target implies 1.9% upside from the Oct. 29 close of $43.18. M impact | EQUITY | Oct 30, 2026, 11:05 AM UTC Citizens Financial Services Reports Unaudited Third-Quarter 2026 Results M impact | EQUITY | Oct 30, 2026, 11:05 AM UTC